AI-Assisted Variant Reinterpretation Global Market Report 2026

The artificial intelligence (AI)-assisted variant reinterpretation market size has grown exponentially in recent years. It will grow from $1.76 billion in 2025 to $2.14 billion in 2026 at a compound annual growth rate (CAGR) of 21.8%. The growth in the historic period can be attributed to growing availability of genomic data, rising need for accurate variant classification, adoption of AI in clinical research, increasing regulatory emphasis on diagnostic accuracy, expansion of precision medicine initiatives.

The artificial intelligence (AI)-assisted variant reinterpretation market size is expected to see exponential growth in the next few years. It will grow to $4.76 billion in 2030 at a compound annual growth rate (CAGR) of 22.1%. The growth in the forecast period can be attributed to growing integration of machine learning and deep learning platforms, increasing adoption of natural language processing for literature review, rising demand for cloud-based deployment, expansion of AI-assisted drug development, increasing focus on real-time variant monitoring and reinterpretation. Major trends in the forecast period include increasing adoption of cloud-based variant reinterpretation platforms, rising demand for ai-enabled clinical decision support, growing integration with electronic health records (ehr), expansion of real-time data annotation and labeling tools, rising focus on personalized medicine and patient-centric diagnostics.

The rising demand for personalized medicine is anticipated to fuel the expansion of the artificial intelligence (AI)-assisted variant reinterpretation market throughout the forecast period. Personalized medicine focuses on customizing medical treatments and therapies for individual patients based on their genetic profiles, biomarkers, and specific disease characteristics. This demand is growing as advancements in genomic sequencing technologies and molecular diagnostics enable more accurate identification of genetic variants and facilitate individualized treatment decisions that enhance clinical outcomes. AI-assisted variant reinterpretation serves a vital function in personalized medicine by effectively analyzing and reanalyzing genetic variants as new clinical evidence becomes available. These solutions assist clinicians and researchers in generating precise, patient-specific insights for diagnosis, treatment selection, and risk evaluation, while minimizing the time and complexity involved in manual variant interpretation. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Therefore, the rising demand for personalized medicine is propelling the growth of the artificial intelligence (AI)-assisted variant reinterpretation market.

Leading companies operating in the artificial intelligence (AI)-assisted variant reinterpretation market are increasingly focusing on developing innovative solutions such as explainable AI-powered variant ranking systems to streamline genetic variant interpretation and improve diagnostic accuracy. An AI-powered variant ranking system is a machine-learning-based tool that automatically scores and prioritizes genetic variants according to their likelihood of pathogenicity, enabling clinicians and geneticists to concentrate on the most clinically relevant findings. For example, in October 2024, SeqOne S.A.S., a France-based AI-driven genomic software company, launched the DiagAI Score, an explainable AI-powered metric that assesses and ranks genetic variants on a 0-100 scale based on pathogenicity, phenotype relevance, inheritance patterns, and data quality criteria. The solution incorporates advanced components such as the Universal Pathogenicity Predictor (UP²) and Phenogenius to generate clinically meaningful scores while preserving human expert oversight.

In May 2025, GeneDx Holdings Corp., a US-based healthcare technology company, completed the acquisition of Fabric Genomics for an undisclosed sum. Through this acquisition, GeneDx intends to expedite its progression into the next stage of genomic medicine by integrating its comprehensive rare disease testing expertise with AI-driven genomic interpretation, thereby broadening decentralized testing, improving diagnostic precision, and expanding its global market presence. Fabric Genomics Inc. is a US-based healthcare technology company specializing in artificial intelligence (AI)-assisted variant reinterpretation and analysis through its Fabric Enterprise platform, which features the Fabric GEM AI algorithm.

Major companies operating in the artificial intelligence (AI)-assisted variant reinterpretation market are Illumina Inc., Tempus Labs Inc., Invitae Corporation, MedGenome Labs Private Limited, SOPHiA GENETICS S.A., Genomenon Inc., DNAnexus Inc., Alstronix Technologies Pvt Ltd, Lifebit Genomics Ltd, Strand Life Sciences Private Limited, Galatea Bio Inc., Clear Labs Inc., Congenica Ltd, Epigene Labs Pvt Ltd, Genoox Ltd, Breakthrough Genomics Inc., Genix.ai Inc., Nostos Genomics Inc., Variant Bio Inc., SeqOne Systems S.A.

North America was the largest region in the artificial intelligence (AI)-assisted variant reinterpretation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-assisted variant reinterpretation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-assisted variant reinterpretation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI)-assisted variant reinterpretation market includes revenues earned by entities by providing services such as genetic variant classification, automated pathogenicity prediction, clinical report generation, data integration and annotation, and reinterpretation updates. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artificial intelligence (AI)-assisted variant reinterpretation involves using AI technologies to examine and reassess genetic variants in the context of new scientific findings, clinical information, or revised guidelines. This process enables clinicians and researchers to update variant classifications, improving diagnostic precision and informing patient care decisions.

The key components of artificial intelligence-assisted variant reinterpretation include software and services. Software refers to advanced analytical platforms that utilize algorithms and computational models to continuously reassess genetic variants and enhance classification accuracy. These solutions are developed using machine learning, deep learning, neural networks, and natural language processing technologies, and are deployed through cloud-based and on-premises models. Applications include clinical diagnostics, research, drug development, personalized medicine, and other areas, serving end users such as hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and other end-users.

Tariffs on imported AI software platforms, computational hardware, and bioinformatics tools are impacting the AI-assisted variant reinterpretation market by increasing deployment and operational costs, particularly affecting cloud-based and on-premises software solutions. Regions such as North America, Europe, and Asia-Pacific, which rely on imported AI and genomic analytics tools, are most affected. While tariffs increase costs, they also encourage local software development, promote domestic bioinformatics infrastructure, and drive innovation in cost-effective variant reinterpretation solutions, creating long-term opportunities for regional providers.

The artificial intelligence (AI)-assisted variant reinterpretation market research report is one of a series of new reports that provides artificial intelligence (AI)-assisted variant reinterpretation market statistics, including artificial intelligence (AI)-assisted variant reinterpretation industry global market size, regional shares, competitors with a artificial intelligence (AI)-assisted variant reinterpretation market share, detailed artificial intelligence (AI)-assisted variant reinterpretation market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-assisted variant reinterpretation industry. This artificial intelligence (AI)-assisted variant reinterpretation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.